AI stock analysis · Diagnostics & Research · Last analyzed Aug 17, 2026
Compass Score
3.0/5
Call
Hold
Price
$202.45
AI Target
$227.96 +12.6%
AI Analyst Summary
Danaher is executing a compelling earnings recovery, with 59.7% YoY EPS growth reflecting bioprocessing demand normalization and the Danaher Business System's operational leverage — a dynamic that 22 of 23 covering analysts view as a Buy. The forward P/E of 21.8x and PEG of 1.32 suggest the market has not yet fully re-rated the stock for this recovery cycle, leaving meaningful upside to the consensus target. The key risk is that bioprocessing end-market demand remains lumpy, and any renewed inventory destocking among biopharma customers could reset near-term estimates sharply.
Catalysts
Bioprocessing revenue acceleration in upcoming quarters as biopharma customer inventory destocking fully clears, potentially driving upside surprises to the 5.5% revenue growth rate
Continued EPS beat momentum in Q2/Q3 earnings reports, with operating margin expansion from the Danaher Business System providing a recurring positive revision catalyst
Potential M&A activity or capital deployment announcements that could unlock incremental growth vectors, consistent with Danaher's historically disciplined acquisition strategy
Fundamentals
PeTrailing P/E 36.1x / Forward P/E 21.8x · 3.0/5
Trailing P/E of 36.1x is elevated relative to the broader healthcare sector median, but the forward P/E of 21.8x suggests meaningful earnings normalization ahead. Valuation is not cheap outright but is more reasonable on a forward basis given the growth recovery profile.
PegPEG 1.32 · 4.0/5
PEG of 1.32 is comfortably below 2.0 and reflects a growth-adjusted valuation that is attractive relative to large-cap healthcare peers. The strong YoY earnings rebound supports a constructive PEG read.
Analyst RatingStrong Buy consensus (1.5) · 5.0/5
Consensus rating of 1.5 on an inverted scale reflects near-unanimous bullish conviction — 22 Buys against just 4 Holds and zero Sells across 23 analysts. This is an exceptionally strong signal of institutional confidence.
Earnings TrendEPS growth +59.7% YoY · 5.0/5
YoY earnings growth of 59.7% represents a powerful recovery, likely driven by bioprocessing normalization and margin expansion. Revenue growth of 5.5% confirms this is not purely a low-base effect — operational leverage is clearly materializing.
Price Target Beat4 of 4 recent quarters beat · 4.0/5
EPS beat rate of 4 out of 4 recent quarters demonstrates consistent execution against expectations. Only partial history (4 quarters vs. the full 8-quarter window) limits a score of 5, but the trend is clearly positive.
ManagementConsistent executor with strong analyst trust · 4.0/5
A perfect recent EPS beat record combined with near-unanimous analyst Buy ratings signals high confidence in management's ability to guide and deliver. Capital allocation discipline under the Danaher Business System is well-regarded. Score capped at 4 due to limited beat history window.
● See the full picture
Get today's top-scored picks, ranked for you.
Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.
Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →
Not financial advice.
Compass is an analytical tool, not a registered investment adviser or broker-dealer.
Scores and recommendations are generated by AI, may be inaccurate or out of date, and are
not investment, financial, legal, or tax advice. Investing involves risk, including loss of
principal. Do your own research and consult a licensed financial professional.
About Compass.